Show simple item record

dc.contributor.authorSeib, Kate L
dc.description.abstractIntroduction Gonorrhoea is becoming increasingly difficult to control due to antibiotic resistance and the absence of a vaccine. However, a vaccine to the closely related bacteria Neisseria meningitidis, the outer membrane vesicle (OMV) vaccine MeNZB, was reported to be associated with reduced rates of gonorrhoea. To investigate this possible cross-protection we assessed serum raised to the meningococcal vaccine Bexsero, which contains the MeNZB OMV component plus three recombinant antigens (NadA, fHbp-GNA2091, NHBA-GNA1030), in terms of its cross reactivity and functional activity against Neisseria gonorrhoeae. Methods The similarity of MeNZB and Bexsero antigens to gonococcal proteins was assessed bioinformatically. Sera from rabbits immunised with the OMV component or the three recombinant antigens of Bexsero, and sera from humans immunised with Bexsero were tested in Western blot, ELISA, serum bactericidal activity (SBA) and neutrophil opsonophagocytic (OPA) assays to assess the level and functional activity of antibodies recognising N. gonorrhoeae. Results There is a high level of sequence identity between MeNZB/Bexsero OMV antigens and gonococcal proteins. NHBA is the only Bexsero recombinant antigen that is conserved and surfaced exposed in N. gonorrhoeae. Rabbit antibodies to the OMV component or to the three recombinant antigens of Bexsero recognise gonococcal proteins and mediate SBA and OPA killing of N. gonorrhoeae. Furthermore, Bexsero induces antibodies in humans that recognise gonococcal proteins. Analysis of the functional activity of Bexsero-induced human antibodies against N. gonorrhoeae is ongoing. Conclusions The ability of antibodies induced by MeNZB OMV proteins to recognise and kill N. gonorrhoeae could explain the decrease in gonococcal cases associated with MeNZB vaccination. The presence of antibodies to OMV proteins plus NHBA following Bexsero vaccination may result in additional protection against gonorrhoea. Analysis of Bexsero-vaccinate human sera may also facilitate the identification of a correlate of protection to guide future development of a gonococcal vaccine.en_US
dc.publisherBMJ Publishing Group Ltden_US
dc.relation.ispartofconferencenameSTI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI)en_US
dc.relation.ispartofconferencetitleSexually Transmitted Infectionsen_US
dc.relation.ispartoflocationVancouver, Canadaen_US
dc.relation.ispartofissueSuppl 1en_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.fieldofresearchMedical Microbiologyen_US
dc.subject.fieldofresearchPublic Health and Health Servicesen_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsInfectious Diseasesen_US
dc.titleProgress towards a Gonorrhoea vaccineen_US
dc.typeConference outputen_US
dc.type.descriptionE3 - Conferences (Extract Paper)en_US
dcterms.bibliographicCitationSeib, KL, Progress towards a Gonorrhoea vaccine, Sexually Transmitted Infections, 2019, 95 (Suppl 1), pp. A20-A20en_US
gro.hasfulltextNo Full Text
gro.griffith.authorSeib, Kate

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record